CQ and HCQ treatment inhibit the growth of ATLL and HTLV-1-infected T-cell lines derived from HAM/TSP patients in vitro.

(A) Four ATLL cell lines (Su9T01, KK1, S1T, and MT2), two T-ALL cell lines (MOLT4 and JURKAT), and PBMCs from a healthy donor were treated with 50 μM CQ or 25 μM HCQ for 48 hours. Cell viability was determined by trypan blue. Relative cell viability was calculated based on the percentage of untreated cells (0 μM). Data are presented as the mean ± SD (n = 3). *p < 0.05 for Su9T01, KK1, S1T, MT2, MOLT4, or JURKAT cells compared to healthy PBMCs, respectively. (B) HCT1, HCT4, and HCT5 cell lines were treated with varying concentrations of CQ or HCQ for 48 hours. The relative cell viability was calculated as the percentage of untreated cells (0 μM). Data are presented as the mean ± SD (n = 3). *, #, or + P < 0.05, HCT1, HCT4, or HCT5 compared to Healthy PBMC, respectively.

(TIF)